Publisher
Springer Nature Switzerland
Reference28 articles.
1. Bank, P.C., Caudle, K.E., Swen, J.J.: Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. Clin. Pharmacol. Ther. 103, 599–618 (2018)
2. Ahmed, S.: Pharmacogenomics of drug metabolizing enzymes and transporters: Relevance to precision medicine. Genomics Proteomics Bioinform. 14(5), 298–313 (2016)
3. Preissner, S.C.: Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE 8(12), e82562 (2013)
4. Ibeanu, G.C., Goldstein, J.A.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharma. Experim. Therap. 286(3), 1490–1495 (1998). PMID 9732415
5. Fukushima-Uesaka, H.: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet. 20(4), 300–307 (2005).
https://doi.org/10.2133/dmpk.20.300. PMID16141610